Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.57 |
| ▸ | NPY1R | P25929 | 11/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.57 |
| ▸ | NPY2R | P49146 | 7/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621730 | 1.00 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30493150 | 1.00 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30544772 | 0.98 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL31232438 | 0.98 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL29422322 | 0.98 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30527822 | 0.98 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL29405969 | 0.98 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30272480 | 0.98 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30355263 | 0.97 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30490411 | 0.96 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304178-A1 | Peptides and Their Use in the Treatment of Skin | AVON PRODUCTS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2016105375-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF SKIN | AVON PRODUCTS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304178-A1 | Peptides and Their Use in the Treatment of Skin | CUTA, IGFBP4, VIP | NPY4R 405/4885NPY1R 1262/4885NPY5R 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.